We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    caverstem
Previous Study | Return to List | Next Study

Autologous Bone Marrow Concentrate in Treatment of Erectile Dysfunction.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03699943
Recruitment Status : Completed
First Posted : October 9, 2018
Last Update Posted : September 6, 2019
Information provided by (Responsible Party):
Creative Medical Health, Inc.

Brief Summary:
This study assessed the safety and efficacy of autologous bone marrow concentrate and injected intra-cavernously into patients with erectile dysfunction (ED). Specifically, this study will evaluate ED treatment >18 year old men, a demographic where the etiology of ED is attributable primarily to the loss of corporal smooth muscle in the penis. Study endpoints will evaluate the safety and efficacy of intracavernosal bone marrow concentrate administration for treating ED patients.

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Procedure: CaverStem Not Applicable

Detailed Description:

Erectile dysfunction (ED) is characterized by abnormalities of the vascular system; most commonly, venous leakage (or veno-occlusive dysfunction) resulting from loss of integrity of the surrounding corporal smooth muscle. In the penile vascular system, the corporal smooth muscle is responsible for trapping the blood delivered to the corpora cavernosa via the arterial system.

Bone marrow is enriched for cells with regenerative potential, including mesenchymal stem cells, which accelerate healing of damaged tissue. The possibility of using bone marrow cells in the treatment of ED is enticing since stem/progenitor cell populations are known to secrete various growth factors, possess anti-inflammatory activities, and can differentiate into cells of the penile architecture.

This study will evaluate safety and efficacy of autologous bone marrow concentrate generated by a closed system device and injected intra-cavernously in 40 patients aged > 18 years of age diagnosed with erectile dysfunction with low dose 30 cc (20 patients) or high dose 60 cc (20 patients). Safety and efficacy will be evaluated at baseline (prior to treatment) and at 1,3,6 and 12-month follow up visits. The study will determine whether injection of bone marrow cells intra-cavernously is a clinically feasible, safe and reproducible approach for treating erectile dysfunction. A clinical registry will also be enrolling treating the same patient population (100 patients (20 cc)).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Caverstem 1.0 - Low dose - 30 cc - 20 patients Caverstem 1.0 - High dose - 60 cc - 20 patients Caverstem 2.0 - 20 cc - 100 patients
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Feasibility Study of Intra-cavernosal Administration of Non-Expanded Autologous Bone Marrow Concentrate in Treatment of Erectile Dysfunction.
Actual Study Start Date : December 8, 2015
Actual Primary Completion Date : August 31, 2018
Actual Study Completion Date : August 31, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: CaverStem 1.0 - Low
Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. low dose 30 cc
Procedure: CaverStem
Active Comparator: CaverStem 1.0 - High
Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. high dose 60 cc
Procedure: CaverStem
Active Comparator: Caverstem 2.0 - Clinical Registry
Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. 20 cc
Procedure: CaverStem

Primary Outcome Measures :
  1. Improvement in erectile function as measured by total score in the International Index of Erectile Function [ Time Frame: 6 months ]
    IIEF-5 scale

  2. Rate of Adverse Events [ Time Frame: 6 months ]
    bruising, infection, pain

Secondary Outcome Measures :
  1. Change in Doppler Measurements [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Chronic organic ED duration at least 0.5 years
  2. Diagnosis of ED based on Doppler Ultrasound and/or dynamic infusion cavernosonometry.
  3. Baseline International Index of Erectile Function (IIEF-5) score of < 21
  4. Oral medications and intracavernous pharmacological approaches have been deemed ineffective, contraindicated or cannot be tolerated.
  5. Concurrently undergoing treatment with testosterone.
  6. Willing to forego any other treatments for ED over the course of the study.

Exclusion Criteria:

  1. Subjects using any medications/drugs with known effects on erectile function within 4 weeks of the study period, including certain antidepressants, antihistamines, diuretics, and beta-blockers.
  2. Subjects using herbal remedies for addressing erectile dysfunction within one month of study initiation.
  3. Subjects with penile prosthesis or other urinary prosthesis.
  4. Subjects with penile anatomical deformities (e.g. Peyronie's disease) or history of priapism.
  5. Previous penile surgeries for erectile dysfunction, premature ejaculation or penile enlargement.
  6. Diagnosis of psychogenic ED as determined by nocturnal tumenscence testing.
  7. Presenting with uncontrolled or severe disease, including cardiovascular disease, diabetes, liver disease.
  8. Uncontrolled hypertension or hypotension (systolic blood pressure > 170 or < 90 mm Hg, and diastolic blood pressure > 100 or < 50 mm Hg)
  9. Suffered a cardiovascular event within 6 months prior to study initiation.
  10. Current or previous malignancy other than non-melanoma skin cancer (successfully treated or treatable by curative excision or other local curative therapy).
  11. Diagnosis of a systemic autoimmune disorder.
  12. Receiving immunosuppressant medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03699943

Layout table for location information
United States, California
Harbor - UCLA Medical Center
Torrance, California, United States, 90502
Sponsors and Collaborators
Creative Medical Health, Inc.
Layout table for investigator information
Study Chair: Alex Gershman UCLA/Cedar
Study Director: Jacob Rajfer University of California, Los Angeles
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Creative Medical Health, Inc.
ClinicalTrials.gov Identifier: NCT03699943    
Other Study ID Numbers: 21511-01
First Posted: October 9, 2018    Key Record Dates
Last Update Posted: September 6, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data will be shared among other investigators through secure clinical registry.
Supporting Materials: Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: 1 year

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Genital Diseases, Male
Genital Diseases
Urogenital Diseases
Sexual Dysfunction, Physiological
Male Urogenital Diseases
Sexual Dysfunctions, Psychological
Mental Disorders